New Drug: Glofitamab in Large B-Cell Lymphoma

  • Study

    Phase I-II, open-label, multicenter study
    Relapse or refractory large cell lymphoma
    Glofitamab (n=132)


  • Efficacy

    cORR: 56% [74 of 132 pts]
    CR: 43% [ 56 of 132 pts]
    mDoR: 18.4 mos [11.4-NR]

  • Safety

    Grade3: CRS (4.3%), ICANS (4.8%)


    • https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf

    https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf

    http://www.ncbi.nlm.nih.gov/pubmed/0

    Reviewed by Elvin Chalabiyev, MD on Aug 20, 2023

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag